Oncologic surveillance following radical cystectomy: an individualized risk-based approach

Merrill, Suzanne; Boorjian, Stephen; Thompson, R.; Psutka, Sarah; Cheville, John; Thapa, Prabin; Tollefson, Matthew; Frank, Igor
December 2017
World Journal of Urology;Dec2017, Vol. 35 Issue 12, p1863
Academic Journal
Purpose: To provide an alternative surveillance approach for bladder cancer (BC) following radical cystectomy (RC) according to more accurate predictions of a patient's projected BC course. Methods: We identified 1797 patients who underwent RC for M0 BC between 1980 and 2007. Patients were stratified by pathologic stage (pT0Nx-0, pTa/CIS/1Nx-0, pT2Nx-0, pT3/4Nx-0, and pTanyN+), relapse location (urethra, upper tract, abdomen/pelvis, chest, and other), age (≤60, 61-70, 71-80, >80 years) and Charlson Co-morbidity Index (CCI ≤2 and CCI ≥3). Risks of disease recurrence and non-BC death were modeled using Weibull distributions. Recommended surveillance durations were estimated when the risk of non-BC death exceeded the risk of recurrence. Results: At a median follow-up of 10.6 years (IQR 6.8,15.2), 713 patients developed recurrence. Vastly different recurrence patterns were appreciated. Specifically, among patients ≤60 years with pT2Nx-0, non-BC death risk exceeded the risk of recurrence in the abdomen at 7.5 years following surgery when CCI was ≥3, versus at year 10 after RC when CCI was ≤2. Meanwhile, for patients >80 years with pT2Nx-0, non-BC death risk exceeded the risk of abdominal recurrence at 1 year after RC, regardless of CCI. Conclusion: We present an alternative post-RC surveillance approach that incorporates a patient's changing risk profile with the influence of competing health factors. We believe this strategy provides more individualized recommendations than current guidelines, and may improve the benefit derived from surveillance while reducing resource misappropriation.


Related Articles

  • Maximal Survival and Quality of Life for Patients with Invasive Bladder Cancer. Packiam, Vignesh T.; Patel, Sanjay G.; Steinberg, Gary D. // AUANews;Sep2015, Vol. 20 Issue 9, p11 

    In this article, the authors' discusses about survival and quality of life for patients with invasive bladder cancer. Topics include difficulties associated with comparison of survival between patients undergoing radical cystectomy and trimodal therapy, guidelines of the American Urological...

  • The Outcome of the Intravesical BCG Treatment in Naive Positive Tuberculin Skin Test Non-Muscle Invasive Bladder Cancer Patients. Shusit Parnitvitidkun // Thai Journal of Surgery;Jan-Mar2012, Vol. 33 Issue 1, p17 

    Purpose: To study one-year outcome of intravesical Bacillus Calmette-Guerin (BCG) treatment in patients with non-muscle invasive bladder cancers. Materials and Methods: From May 2008 to August 2009, 12 patients with primary non-muscle invasive bladder cancers were treated with TUR-BT followed by...

  • The role of radiotherapy in bladder cancer. Pinnarò, Paola; Giordano, Carolina; Giovinazzo, Giuseppe; Saracino, Biancamaria // Urologia;2013, Vol. 80 Issue 3, p202 

    In this article we report on the current role of radiotherapy in the management of non-muscle invasive as well as in muscle invasive bladder cancer. Radiotherapy seems to have no role in non-muscle invasive bladder cancer. In muscle invasive bladder tumors, the role of radiotherapy is under...

  • Keep Bladder Cancer at Bay.  // Cleveland Clinic Men's Health Advisor;Jan2014, Vol. 16 Issue 1, p3 

    The article discusses the guidelines and recommendations for patients with bladder cancer to minimize the dangerous risks. According to the American Cancer Society (ACS) Inc., more than 54,000 men has developed bladder cancer in 2013 making it the fourth-most common cancer in men. It also...

  • Nuclear Matrix Protein 22 in Voided Urine Cytology Efficacy in Risk Stratification for Carcinoma of Bladder. Sankhwar, Monica; Singh, Rajender; Sankhwar, Satya Narayan; Goel, Madhu Mati; Jain, Amita; Sankhwar, Pushp Lata // World Journal of Oncology;2013, Vol. 4 Issue 3, p151 

    Background: To investigate the nuclear matrix protein NMP22 in voided urine for detection of malignancy in patients with risk factors of symptoms of bladder cancer. Methods: January 2009 to December 2012, participants included 1,331 patients at elevated risk for bladder cancer due to factors...

  • Bladder cancer index: cross-cultural adaptation into Spanish and psychometric evaluation. Schmidt, Stefanie; Riel, Ricard; Frances, Albert; Lorente Garin, José Antonio; Bonfill, Xavier; Martinez-Zapata, María José; Suarez-Varela, Maria Morales; dela Cruz, Javier; Emparanza, José Ignacio; Sánchez, María-José; Zamora, Javier; Ramos Goñi, Juan Manuel; Alonso, Jordi; Ferrer, Montse // Health & Quality of Life Outcomes;2014, Vol. 12 Issue 1, p1 

    Background The Bladder Cancer Index (BCI) is so far the only instrument applicable across all bladder cancer patients, independent of tumor infiltration or treatment applied. We developed a Spanish version of the BCI, and assessed its acceptability and metric properties. Methods For the...

  • Achieving the achievable in muscle-invasive bladder cancer. Booth, Christopher M.; Macklllop, William J. // Canadian Urological Association Journal;Aug2012, Vol. 6 Issue 4, p251 

    The author reflects on the achievable cure of the patients suffering from muscle-invasive bladder cancer (MIBC). He discusses the outcomes obtained by the clinical trials and case series regarding the cancer. He also opines that managing the MIBC is a tedious task but it may be tackled by a...

  • Bladder Cancer in the Elderly: Balancing Disease and Surgical Risk. CANTER, DANIEL J. // Renal & Urology News;Nov2013, Vol. 12 Issue 11, p25 

    The article discusses bladder cancer in older people, focusing on the need to balance the disease and risk associated with surgical procedure. It states that older patients with bladder cancer have greater perioperative and postoperative mortality, highlighting the importance of being careful in...

  • miR-19a acts as an oncogenic microRNA and is up-regulated in bladder cancer. Yougang Feng; Jun Liu; Yongming Kang; Yue He; Bo Liang; Ping Yang; Zhou Yu // Journal of Experimental & Clinical Cancer Research (17569966);2014, Vol. 33 Issue 1, p1 

    Background The application of microRNAs (miRNAs) as potential biomarkers and therapy targets has been widely investigated in many kinds of cancers. The discovery of tumor associated miRNAs in serum of patients supported the use of plasma/serum miRNAs as noninvasive means of cancer detection....

  • Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer. Ying-Li Lin; Yan-Ling Wang; Jian-Guo Ma; Wen-Ping Li // Journal of Experimental & Clinical Cancer Research (17569966);2014, Vol. 33 Issue 1, p1 

    Background PCDH8 is a novel tumor suppressor gene, and frequently inactivated by promoter methylation in human cancers. However, there is little information regarding PCDH8 methylation in non-muscle invasive bladder cancer (NMIBC). The aim of this study was to investigate the methylation status...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics